healthbook ESC 2018 Newsroom

healthbook’s Independent Conference Highlights*

 

Expert Opinions

Video published with permission from
Prof. Dr Steffel
Personal Highlights 
Interview with Prof. Dr Jan Steffel
Prof. Steffel elaborates on his personal highlights of ESC 2018 and discusses the data presented on anticoagulation, use of aspirin for primary prevention of cardiovascular events, as well as data from additional practice-changing studies.

Watch the video interview here >>>

Video published with permission from
PD Dr Sudano
Personal Highlights
Interview with PD Dr Isabella Sudano
PD Dr Sudano provides her personal highlights of ESC 2018 with a special emphasis on the new ESC/ESH Guidelines on Arterial Hypertension.

Watch the video interview here >>>

Access the 2018 ESC/ESH Guidelines here >>>

Video published with permission from
PD Dr Eckstein
Smart Wearables in Cardiology
Interview with PD Dr Jens Eckstein
PD Dr Eckstein provided a summary of his presentation on “Device-agnostic platform for automatic data capture from biomedical mobile sensors or wearables in clinics” providing insights on the innovative aspects of this new platform.

Watch the video interview here >>>

 

 

Study Highlights
  Stroke Prevention
Stroke Prevention: State of the Art in Patients with Atrial Fibrillation
Vitamin K antagonists such as warfarin were the first therapeutic options that showed not only a two third (64%) reduction in the risk of developing a stroke but also a reduction in mortality in atrial fibrillation patients.
Read more
Reference: Steffel. Stroke prevention in atrial fibrillation – State of the art. Oral presentation 1457 presented at: ESC 2018; 25–29 August; Munich, Germany.

 

  Coronary Artery Disease & Peripheral Artery Disease
Managing Patients With Coronary Artery Disease (CAD) and Peripheral Artery Disease (PAD) – Results From the COMPASS Trial
The randomised trial COMPASS evaluated the impact of adding 2.5 mg twice daily rivaroxaban to aspirin on cardiovascular events in patients with CAD or PAD.
Read more
Reference: Eikelboom et al. How to manage patients with chronic coronary artery disease and peripheral artery disease. Oral presentation 5146 presented at: ESC 2018; 25–29 August; Munich, Germany.

 

  Atherosclerotic Events
Impact of Canakinumab on Atherosclerotic Events and Mortality – Results From the CANTOS Trial
The CANTOS trial highlighted the importance of assessing interleukin (IL)-6 levels at baseline and during treatment in patients receiving canakinumab. Lower IL-6 levels at baseline were associated with a reduced rate of nonfatal myocardial infarction, nonfatal stroke and cardiovascular death (MACE).
Read more
Reference: Ridker et al. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS). European Heart Journal. 39(suppl_1):ehy310.
Visit the full text of the original publication on academic.oup.com

 

  Preventive Cardiology
Aspirin for Prevention of Cardiovascular Disease in Patients With Diabetes – Results from the ASCEND Trial
The randomised trial ASCEND enrolled 15,480 adult patients in the UK with diabetes but without cardiovascular disease at baseline.
Read more
Reference: Armitage et al. ASCEND – A randomized trial of aspirin versus placebo for primary cardiovascular prevention in 15,480 people with diabetes. Oral presentation 2315 presented at: ESC 2018; 25–29 August; Munich, Germany.

 

  Anticoagulation
Extended Rivaroxaban in Medically Ill Patients – Results From the MARINER Trial
The randomised MARINER trial is an event-driven study that aimed at optimizing the risk/benefit profile of extended prophylaxis with rivaroxaban and included over 12,000 medically ill patients who were hospitalized for 3–10 days.
Read more
Reference: Spyropoulos et al. MARINER – Medically Ill Patient Assessment of Rivaroxaban Versus Placebo IN Reducing Post-Discharge Venous Thrombo-Embolism Risk. Oral presentation 2066 presented at: ESC 2018; 25–29 August; Munich, Germany.

 

  Hypertension Guidelines
New ESC Hypertension Guidelines
The new ESC guidelines on arterial hypertension were presented in two separate presentations. While the definition of hypertension was unchanged, these new guidelines include a new concept of high normal blood pressure. Patients in this group required strict monitoring and treatment is only recommended in those patients with high cardiovascular risk. Furthermore, the guidelines now recommend the use of combination therapy as soon as possible to increase the patient compliance and the blood pressure control.
Read the new ESC guidelines on hypetension here >>>
References:
Williams. 2018 ESC/ESH Guidelines on Arterial Hypertension – Part 1. Oral presentation 1053 presented at: ESC 2018; 25–29 August; Munich, Germany.
Mancia. 2018 ESC/ESH Guidelines on Arterial Hypertension – Part 2. Oral presentation 1054 presented at: ESC 2018; 25–29 August; Munich, Germany.

 

  Hypertension
Long-Term Impact of Blood Pressure-Lowering and Lipid-Lowering Therapy
ASCOT Legacy is the first study to evaluate the impact of both blood pressure-lowering and lipid-lowering therapy on cardiovascular mortality in hypertensive patients. In total 8,850 patients in the UK were first randomised 1:1 to receive either atenolol- or amlodipine-based therapy.
Read more
Reference: Gupta et al. Long-term mortality after the blood pressure and lipid-lowering treatment in hypertensive patients: 16-year follow-up of the ASCOT Legacy study. Oral presentation 1327 presented at: ESC 2018; 25–29 August; Munich, Germany.

 

  Arrhythmia
Quality of Life in Patients Receiving Catheter Ablation Versus Antiarrhythmic Drug Therapy

The CABANA trial of atrial fibrillation showed incremental and clinically meaningful improvements in atrial fibrillation-related symptoms and quality of life in patients receiving catheter ablation versus antiarrhythmic drug therapy.
Read more
Reference: Mark et al. CABANA Trial – Quality of Life in the Catheter Ablation Versus Antiarrhythmic Drug Therapy for Atrial Fibrillation. Oral presentation 2207 presented at: ESC 2018; 25–29 August; Munich, Germany.

 

  Anticoagulation
Rivaroxaban for Patients With Heart Failure – Results From the COMMANDER HF Trial
The COMMANDER HF trial investigated whether 2.5 mg twice daily rivaroxaban added to background antiplatelet therapy reduces rates of deaths or cardiovascular events in high-risk patients with recent worsening of chronic heart failure, reduced ejection fraction and coronary artery disease.
Read more
Reference: Zannad et al. COMMANDER HF – Randomized Study Comparing Rivaroxaban with Placebo in Subjects with Heart Failure and Significant Coronary Artery Disease Following an Episode of Decompensated Heart Failure. Oral presentation 3238 presented at: ESC 2018; 25–29 August; Munich, Germany.

 

  Smart Wearables in Cardiology
New Device-Agnostic Platform for Clinical Trials
Swiss experts have developed a new device-agnostic platform that can be used in clinical trials. Using mobile sensors or wearables the health status of patients is automatically captured and sent to a local server of the health care provide for storage and read out.
Read more
Reference: Mutke et al. Device-agnostic platform for automatic data capture from biomedical mobile sensors or wearables in clinics. Oral presentation presented at: ESC 2018; 25–29 August; Munich, Germany.

 

  Atrial Fibrillation
Comparison of Atrial Fibrillation Detection Algorithms in Smart Devices
This analysis compared two atrial fibrillation detection algorithms used in fingertip single lead ECGs (iECGs): The primarily used algorithm (algorithm A) detects p-waves and the second algorithm (algorithm B) uses non-linear beat-to-beat variabilities of pulse waves to discriminate between sinus rhythm and absolute arrhythmia.
Read more
Reference: Mutke et al. Comparing atrial fibrillation detection algorithms in smart devices on validated mobile ECG data. European Heart Journal. 39(suppl_1):ehy565.P1938. Obtained from the ESC website esc365.escardio.org

 

  Functional Mitral Regurgitation
Contemporary Management of Functional Mitral Regurgitation
Three case studies, which were presented at ESC 2018, illustrated that functional mitral regurgitation (FMR) adds to the burden of heart failure due to a volume overload on a compromised left ventricle.
Read more
Reference: Flammer. Functional mitral regurgitation: assessment and contemporary management. Oral presentation 4107 presented at: ESC 2018; 25–29 August; Munich, Germany.

 

  Chronic Heart Failure
Sacubitril Plus Valsartan in High-Risk Patients With Ongoing Chronic Heart Failure
This retrospective study characterised the tolerability and safety of sacubitril plus valsartan in a real-world patient population with ongoing chronic heart failure.
Read more
Reference: Neiva et al. Tolerability and safety of sacubitril/valsartan in high-risk subgroups. European Heart Journal. 39(suppl_1):ehy564.P911.
Obtained from the ESC website esc365.escardio.org

 

  Heart Failure
Retinal Microvascular Impairment in Heart Failure
This prospective Swiss study investigated the retinal micro- and macrovascular function in patients with heart failure (n=68, of which 30 had preserved ejection fraction), in patients with hypertension (n=58) and in healthy controls (n=77).
Read more
Reference: Barthelmes et al. Retinal microvascular impairment in heart failure with preserved ejection fraction. European Heart Journal. 39(suppl_1):ehy566.P6509. Obtained from the ESC website esc365.escardio.org